S-1: Celularity Inc. Seeks to Raise Capital Through Public Offering of Common Stock and Pre-Funded Warrants

Celularity Inc. announces a public offering of up to 6,521,739 shares of Class A common stock and pre-funded warrants to raise capital for working capital and general corporate purposes.

Summary

• Celularity Inc. is conducting a public offering to sell up to 6,521,739 shares of Class A common stock at an assumed price of $2.30 per share.
• The company is also offering pre-funded warrants to purchase up to 6,521,739 shares of Class A common stock at an exercise price of $0.001 per share.
• The purchase price of each pre-funded warrant is equal to the price per share of Class A common stock minus $0.001.
• The pre-funded warrants are immediately exercisable and may be exercised at any time until all are exercised.
• The company has granted the underwriters a 45-day option to purchase up to an additional 978,260 shares of Class A common stock and/or pre-funded warrants.
• The net proceeds from the offering are intended for working capital and general corporate purposes.
• The company expects to receive net proceeds of approximately $13.3 million, or $15.4 million if the underwriters exercise their option in full.

Sentiment

Score: 3

Explanation: The document highlights significant risks and uncertainties, including the company's financial situation and the challenges of developing novel therapies. While the offering provides a potential source of capital, the overall sentiment is negative due to the company's financial instability and the speculative nature of its business.

Positives

• The offering provides Celularity with additional capital to support its operations.
• The pre-funded warrants offer flexibility to investors who may have ownership limitations.
• The underwriters option to purchase additional shares could result in additional capital for the company.

Negatives

• The offering may cause dilution to existing stockholders.
• The assumed offering price of $2.30 per share may not be indicative of the final offering price.
• There is no established trading market for the pre-funded warrants.

Risks

• Investing in the company's securities is highly speculative and involves a high degree of risk.
• The company has incurred net losses in every period since its inception and anticipates substantial net losses in the future.
• There is substantial doubt about the company's ability to continue as a going concern.
• The company has substantial indebtedness, which is secured by all of its assets.
• The company relies on third parties to conduct potential future clinical trials.
• The FDA regulatory approval process is lengthy and time-consuming, and the company may experience significant delays in the clinical development and regulatory of its therapeutic candidates.
• The company may not be able to file Investigational New Drug applications to commence additional clinical trials on the timelines it expects.
• The company operates its own manufacturing and storage facility, which requires significant resources; manufacturing or other failures could adversely affect its clinical trials and the commercial viability of its therapeutic candidates and its biobanking and degenerative diseases businesses.
• The company relies on donors of healthy human full-term post-partum placentas to manufacture its therapeutic candidates and biomaterials products, and if it does not obtain an adequate supply of such placentas from qualified donors, development of its placental-derived allogeneic cells may be adversely impacted.
• The company's potential future clinical trials may fail to demonstrate the safety and/or efficacy of any of its therapeutic candidates, which would prevent or delay regulatory approval and commercialization.
• If the company's efforts to protect the proprietary nature of the intellectual property related to its technologies are inadequate, it may not be able to compete effectively in its market.
• The company faces significant competition from other biotechnology and pharmaceutical companies, and its operating results will suffer if it fails to compete effectively.
• The company's relationship with customers, physicians, and third-party payors are subject to numerous laws and regulations. If the company or its employees, independent contractors, consultants, commercial partners and vendors violate these laws, it could face substantial penalties.
• The company's business could be materially adversely affected by the effects of health pandemics or epidemics, as well as geopolitical conflicts, inflation, bank failures and recessions, in regions where the company or third parties on which it relies have concentrations of clinical trial sites or other business operations.
• The company will continue to incur significant costs as a result of operating as a public company, and its management will be required to devote substantial time to various compliance initiatives.
• The company disclosed material weaknesses in its internal control over financial reporting. As such, its consolidated financial statements might contain material misstatements and/or it could be required to restate its financial results.

Future Outlook

The company intends to use the net proceeds from this offering for working capital and general corporate purposes.

Industry Context

This offering is taking place in the context of a competitive biotechnology and pharmaceutical industry, where companies are constantly seeking capital to fund research, development, and commercialization efforts.

Comparison to Industry Standards

• The company's approach to cellular therapy using placental-derived cells is novel and may offer advantages over traditional methods, but it also carries significant risks.
• The company's reliance on third parties for clinical trials and manufacturing is common in the industry, but it also introduces risks related to quality and timelines.
• The company's financial situation, including its history of net losses and substantial debt, is not uncommon for early-stage biotechnology companies, but it also raises concerns about its ability to continue as a going concern.
• The company's need for additional capital is typical for companies in this sector, but the availability and terms of such funding are uncertain.

Stakeholder Impact

• Existing stockholders may experience dilution as a result of the offering.
• Potential investors should be aware of the high risks associated with investing in the company.
• The company's employees may be affected by the company's financial situation and any potential changes in operations.

Next Steps

• The company will determine the final offering price of the Class A common stock.
• The company will work with the underwriters to complete the offering.
• The company will use the net proceeds for working capital and general corporate purposes.

Key Dates

Keywords

Class A common stock, pre-funded warrants, public offering, capital raise, biotechnology, regenerative medicine, cellular therapy, biomaterials, clinical trials, FDA approval